$EQ
Equillium, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023061108 Filed on November 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $9.211M $8.870M $0.00
YoY Change -41.55%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.227M $3.520M $4.466M
YoY Change -37.85% -21.18% 54.21%
% of Gross Profit
Research & Development $9.184M $8.974M $8.771M
YoY Change 7.73% 2.31% 25.93%
% of Gross Profit
Depreciation & Amortization $36.00K $30.00K $30.00K
YoY Change 12.5% 0.0% 57.89%
% of Gross Profit
Operating Expenses $12.41M $12.49M $13.24M
YoY Change -9.52% -5.62% 34.24%
Operating Profit -$3.623M -$13.24M
YoY Change -72.63% 34.24%
Interest Expense $517.0K $550.0K -$137.0K
YoY Change -838.57% -501.46% -46.9%
% of Operating Profit
Other Income/Expense, Net $357.0K -$142.0K -$418.0K
YoY Change -55.43% -66.03% -0.71%
Pretax Income -$2.326M -$3.214M -$13.66M
YoY Change -183.88% -76.46% 32.8%
Income Tax $16.00K $500.0K $0.00
% Of Pretax Income
Net Earnings -$2.342M -$3.710M -$13.66M
YoY Change -184.46% -72.83% 32.8%
Net Earnings / Revenue -25.43% -41.83%
Basic Earnings Per Share -$0.11 -$0.40
Diluted Earnings Per Share -$0.07 -$0.11 -$0.40
COMMON SHARES
Basic Shares Outstanding 35.12M 34.57M 34.35M
Diluted Shares Outstanding 34.88M 34.35M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.87M $46.31M $44.52M
YoY Change -42.46% 4.01% -50.91%
Cash & Equivalents $23.22M $34.38M $25.73M
Short-Term Investments $17.65M $11.92M $18.79M
Other Short-Term Assets $4.748M $3.800M $2.254M
YoY Change 65.21% 68.59% 52.71%
Inventory
Prepaid Expenses
Receivables $3.735M $3.800M
Other Receivables $0.00 $0.00
Total Short-Term Assets $49.35M $53.91M $46.78M
YoY Change -35.69% 15.25% -49.25%
LONG-TERM ASSETS
Property, Plant & Equipment $1.111M $313.0K $423.0K
YoY Change 184.14% -26.0% 74.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $70.00K $79.00K $113.0K
YoY Change -32.69% -30.09% 98.25%
Total Long-Term Assets $1.181M $1.314M $1.855M
YoY Change -29.95% -29.16% 518.33%
TOTAL ASSETS
Total Short-Term Assets $49.35M $53.91M $46.78M
Total Long-Term Assets $1.181M $1.314M $1.855M
Total Assets $50.53M $55.23M $48.63M
YoY Change -35.57% 13.56% -47.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.707M $3.635M $2.469M
YoY Change 18.36% 47.23% -7.49%
Accrued Expenses $7.137M $8.304M $6.326M
YoY Change -1.41% 31.27% 63.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $5.714M
YoY Change -100.0% -100.0% 357.12%
Total Short-Term Liabilities $27.57M $28.20M $14.93M
YoY Change -13.94% 88.87% 91.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $4.616M
YoY Change -100.0% -100.0% -47.98%
Other Long-Term Liabilities $384.0K $2.900M $925.0K
YoY Change -96.57% 213.51% 5341.18%
Total Long-Term Liabilities $384.0K $2.900M $4.616M
YoY Change -88.14% -37.18% -48.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $27.57M $28.20M $14.93M
Total Long-Term Liabilities $384.0K $2.900M $4.616M
Total Liabilities $27.96M $31.12M $20.47M
YoY Change -39.85% 52.01% 22.82%
SHAREHOLDERS EQUITY
Retained Earnings -$185.7M -$183.4M -$175.2M
YoY Change 7.73% 4.69% 76.31%
Common Stock $208.2M $207.0M $203.1M
YoY Change 1.91% 1.92% 15.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $22.57M $24.11M $28.16M
YoY Change
Total Liabilities & Shareholders Equity $50.53M $55.23M $48.63M
YoY Change -35.57% 13.56% -47.41%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$2.342M -$3.710M -$13.66M
YoY Change -184.46% -72.83% 32.8%
Depreciation, Depletion And Amortization $36.00K $30.00K $30.00K
YoY Change 12.5% 0.0% 57.89%
Cash From Operating Activities -$5.663M -$1.910M -$13.06M
YoY Change -120.43% -85.38% 86.38%
INVESTING ACTIVITIES
Capital Expenditures $30.00K $20.00K $0.00
YoY Change 1400.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$5.532M $11.00M $15.00M
YoY Change -179.26% -26.67% 42.83%
Cash From Investing Activities -$5.562M $10.98M $15.00M
YoY Change -179.71% -26.8% 43.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 82.00K -260.0K 0.000
YoY Change -106.05% -100.0%
NET CHANGE
Cash From Operating Activities -5.663M -1.910M -13.06M
Cash From Investing Activities -5.562M 10.98M 15.00M
Cash From Financing Activities 82.00K -260.0K 0.000
Net Change In Cash -11.14M 8.810M 1.935M
YoY Change -133.42% 355.3% -46.72%
FREE CASH FLOW
Cash From Operating Activities -$5.663M -$1.910M -$13.06M
Capital Expenditures $30.00K $20.00K $0.00
Free Cash Flow -$5.693M -$1.930M -$13.06M
YoY Change -120.54% -85.23% 87.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001746466
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
eq Research And Experimental Expenditures Capitalized Cost Amortization Period
ResearchAndExperimentalExpendituresCapitalizedCostAmortizationPeriod
P5Y
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38692
dei Entity Registrant Name
EntityRegistrantName
EQUILLIUM, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1554746
dei Entity Address Address Line1
EntityAddressAddressLine1
2223 Avenida de la Playa
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 105
dei Entity Address City Or Town
EntityAddressCityOrTown
La Jolla
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92037
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
412-5302
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
EQ
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35119248
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34382000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59107000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
11924000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
11916000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3769000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2838000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3836000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2874000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
53911000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
76735000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
922000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1191000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
313000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
391000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
79000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
104000
CY2023Q3 us-gaap Assets
Assets
55225000
CY2022Q4 us-gaap Assets
Assets
78421000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3635000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3977000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8304000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7239000
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
15832000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14700000
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
5714000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
428000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
408000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
28199000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32038000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
3239000
CY2023Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2420000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10378000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
498000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
824000
CY2023Q3 us-gaap Liabilities
Liabilities
31117000
CY2022Q4 us-gaap Liabilities
Liabilities
46479000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35119248
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35119248
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34414149
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34414149
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
207045000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
204268000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
458000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
76000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-183398000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-172405000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
24108000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
31942000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55225000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78421000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8870000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26873000
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8974000
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8771000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
27855000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
29022000
eq Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
23049000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3519000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4466000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10340000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12047000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
12493000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
13237000
us-gaap Operating Expenses
OperatingExpenses
38195000
us-gaap Operating Expenses
OperatingExpenses
64118000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3623000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13237000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11322000
us-gaap Operating Income Loss
OperatingIncomeLoss
-64118000
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
267000
us-gaap Interest Expense Debt
InterestExpenseDebt
491000
us-gaap Interest Expense Debt
InterestExpenseDebt
782000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
551000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
130000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1817000
us-gaap Investment Income Interest
InvestmentIncomeInterest
219000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-142000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-281000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-433000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-520000
CY2023Q3 eq Other Income Expense Net
OtherIncomeExpenseNet
409000
CY2022Q3 eq Other Income Expense Net
OtherIncomeExpenseNet
-418000
eq Other Income Expense Net
OtherIncomeExpenseNet
893000
eq Other Income Expense Net
OtherIncomeExpenseNet
-1083000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3214000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13655000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10429000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-65201000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
496000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
564000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3710000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-13655000
us-gaap Net Income Loss
NetIncomeLoss
-10993000
us-gaap Net Income Loss
NetIncomeLoss
-65201000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
19000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
69000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
78000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-165000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
99000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
273000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
304000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
496000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
118000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
342000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
382000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
331000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3592000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13313000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10611000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64870000
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.4
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.4
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.95
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.95
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34878700
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34878700
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34352084
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34352084
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34582574
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34582574
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33512611
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33512611
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
66505000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
18000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1298000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-316000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-37417000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
52630000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
141000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
18000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1302000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
305000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14129000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
40267000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
17000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1189000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
342000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-13655000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
28160000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
31942000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1038000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
229000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3940000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
29269000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
86000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
934000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
35000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3343000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
26981000
CY2023Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
260000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
979000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
118000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34382000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25729000
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
23049000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3710000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
24108000
us-gaap Profit Loss
ProfitLoss
-10993000
us-gaap Profit Loss
ProfitLoss
-65201000
eq Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
23049000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
93000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
86000
us-gaap Share Based Compensation
ShareBasedCompensation
2951000
us-gaap Share Based Compensation
ShareBasedCompensation
3789000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-415000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-519000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
180000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
152000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
749000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-103000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6826000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
931000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1055000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-450000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-323000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1010000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1156000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-476000
eq Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
37000
eq Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
-61000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16119000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36458000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
277000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
37181000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
14962000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
38000000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
26245000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
700000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
804000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11706000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
9133000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
260000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
86000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
141000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-9307000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
141000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-103000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-26000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24725000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24637000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
59107000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50366000
us-gaap Stock Issued1
StockIssued1
22542000
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
507000
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
3000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2017-03-16
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
46300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the condensed consolidated financial statements and accompanying notes. Significant estimates in the Company’s condensed consolidated financial statements relate to accrued research and development expense, expected refunds from the Australian Taxation Office for eligible research and development activities, revenue recognition and the valuation of equity awards. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company’s historical experience, knowledge of current events, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Off-Balance Sheet Ris</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">k</span></p><p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash and cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in which the majority of deposits are in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company’s investment policy includes guidelines for the quality of the related institutions and financial instruments and defines allowable investments that the Company may invest in, which the Company believes minimizes the exposure to concentration of credit risk.</span></p>
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3800000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2800000
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
eq Prepaid And Other Current Assets Tax Incentive
PrepaidAndOtherCurrentAssetsTaxIncentive
1700000
CY2022 eq Prepaid And Other Current Assets Tax Incentive
PrepaidAndOtherCurrentAssetsTaxIncentive
1000000
eq Cumulative Change In Ownership Percentage
CumulativeChangeInOwnershipPercentage
0.50
eq Cumulative Change In Ownership Period
CumulativeChangeInOwnershipPeriod
P3Y
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8534444
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6701166
CY2023Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
11924000
CY2022Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
11916000
CY2022Q4 us-gaap Notes Payable
NotesPayable
9000000
CY2023Q3 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2022Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
11936000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
12000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
11924000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
12006000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
90000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
11916000
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2023Q3 eq Accrued Clinical Development
AccruedClinicalDevelopment
4368000
CY2022Q4 eq Accrued Clinical Development
AccruedClinicalDevelopment
3253000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2359000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2975000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
595000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
472000
CY2023Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
564000
CY2023Q3 eq Accrued Non Clinical Research
AccruedNonClinicalResearch
418000
CY2022Q4 eq Accrued Non Clinical Research
AccruedNonClinicalResearch
465000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
74000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8304000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7239000
CY2019Q3 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2024-06-01
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
922000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
428000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
498000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
926000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y5M19D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0825
us-gaap Operating Lease Payments
OperatingLeasePayments
406000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
120000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
492000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
219000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
169000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
28000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1028000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
102000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
926000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35119248
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34414149
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M23D
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
979000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1189000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2951000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3789000
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10088567
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8178936
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
500000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
600000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0000950170-23-061108-index-headers.html Edgar Link pending
0000950170-23-061108-index.html Edgar Link pending
0000950170-23-061108.txt Edgar Link pending
0000950170-23-061108-xbrl.zip Edgar Link pending
eq-20230930.htm Edgar Link pending
eq-20230930.xsd Edgar Link pending
eq-ex31_1.htm Edgar Link pending
eq-ex31_2.htm Edgar Link pending
eq-20230930_cal.xml Edgar Link unprocessable
eq-20230930_def.xml Edgar Link unprocessable
eq-20230930_lab.xml Edgar Link unprocessable
eq-20230930_pre.xml Edgar Link unprocessable
eq-20230930_htm.xml Edgar Link completed
eq-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable